The impact of migraine and the effect of migraine treatment on workplace productivity in the United States and suggestions for future research

Mayo Clinic Proceedings

Volumn 84, Issue 5, 2009, Pages 436-445

  Burton, Wayne N ^a,b   Landy, Stephen H ^c   Downs, Kristen E ^d   Runken, M Chris ^e  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^d Relevant Health Outcomes Inc   (United States)

^e GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LISINOPRIL; NAPROXEN; TOPIRAMATE; TRIPTAN DERIVATIVE;

ABSENTEEISM; FOLLOW UP; HUMAN; MEDICAL RESEARCH; MIGRAINE; PRODUCTIVITY; QUESTIONNAIRE; REVIEW; SYSTEMATIC REVIEW; UNITED STATES; WORKPLACE;

EID: 66149184433     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/84.5.436     Document Type: Review

References (70)

1. Lipton RB, Scher AI, Kolodner K, Liberman J, Steiner TJ, Stewart WF. Migraine in the United States: epidemiology and patterns of health care use. Neurology. 2002;58(6):885-894. (Pubitemid 34242063)
2. Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: disability and economic costs. Arch Intern Med. 1999;159(8):813-818. (Pubitemid 29200307)
3. Osterhaus JT, Townsend RJ, Gandek B, Ware JE Jr. Measuring the functional status and well-being of patients with migraine headache. Headache. 1994;34(6):337-343. (Pubitemid 24217820)
4. Stewart WF, Ricci JA, Chee E, Morganstein D. Lost productive work time costs from health conditions in the United States: results from the American Productivity Audit. J Occup Environ Med. 2003;45(12):1234-1246. (Pubitemid 37541937)
5. Stang PE, Osterhaus JT. Impact of migraine in the United States: data from the National Health Interview Survey. Headache. 1993;33(1):29-35. (Pubitemid 23057823)
6. Lipton RB, Stewart WF, von Korff M. Burden of migraine: societal costs and therapeutic opportunities. Neurology. 1997;48(3)(suppl 3):S4-S9. (Pubitemid 27120080)
7. US Dept of Labor, Bureau of Labor Statistics. Quarterly census of employment and wages: employment and wages, annual averages 2007. http://www.bls.gov/cew/cewbultn07.htm. Accessed February 10, 2009.
8. Freitag FG. The cycle of migraine: patients' quality of life during and between migraine attacks. Clin Ther. 2007;29(5):939-949. (Pubitemid 47223427)
9. Dahlöf CG, Dimenäs E. Migraine patients experience poorer subjective well-being/quality of life even between attacks. Cephalalgia. 1995;15(1):31-36.
10. Lipton RB, Diamond S, Reed M, Diamond ML, Stewart WF. Migraine diagnosis and treatment: results from the American Migraine Study II. Headache. 2001;41(7):638-645. (Pubitemid 32777746)
11. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988;8(suppl 7):1-96.
12. Tepper SJ, Dahlöf CG, Dowson A, et al. Prevalence and diagnosis of migraine in patients consulting their physician with a complaint of headache: data from the Landmark Study. Headache. 2004;44(9):856-864. (Pubitemid 39362309)
13. Adelman JU, Sharfman M, Johnson R, et al. Impact of oral sumatriptan on workplace productivity, health-related quality of life, healthcare use, and patient satisfaction with medication in nurses with migraine. Am J Manag Care. 1996;2(11):1407-1416. (Pubitemid 126466157)
14. Cohen JA, Beall D, Beck A, et al. Sumatriptan treatment for migraine in a health maintenance organization: economic, humanistic, and clinical outcomes. Clin Ther. 1999;21(1):190-204. (Pubitemid 29106700)
15. Dasbach E, Carides G, Gerth W, Santanello N, Pigeon J, Kramer M. Work and productivity loss in the rizatriptan multiple attack study. Cephalalgia. 2000;20(9):830-834. (Pubitemid 32154564)
16. Davies GM, Santanello N, Gerth W, Lerner D, Block GA. Validation of a migraine work and productivity loss questionnaire for use in migraine studies. Cephalalgia. 1999;19(5):497-502. (Pubitemid 29309040)
17. Fishman P, Black L. Indirect costs of migraine in a managed care population. Cephalalgia. 1999;19(1):50-57. (Pubitemid 29136852)
18. Greiner DL, Addy SN. Sumatriptan use in a large group-model health maintenance organization. Am J Health Syst Pharm. 1996;53(6):633-638. (Pubitemid 26101172)
19. Jhingran P, Cady RK, Rubino J, Miller DW, Grice RB, Gutterman DL. Improvements in health-related quality of life with sumatriptan treatment for migraine. J Fam Pract. 1996;42(1):36-42. (Pubitemid 26030543)
20. Lamb CE, Ratner PH, Johnson CE, et al. Economic impact of workplace productivity losses due to allergic rhinitis compared with select medical conditions in the United States from an employer perspective. Curr Med Res Opin. 2006;22(6):1203-1210. (Pubitemid 44000740)
21. Landy S, DeRossett SE, Rapoport A, et al. Two double-blind, multicenter, randomized, placebo-controlled, single-dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: function, productivity, and satisfaction outcomes. MedGenMed. 2007;9(2):53. (Pubitemid 46902032)
22. Legg RF, Sclar DA, Nemec NL, Tarnai J, Mackowiak J. Cost benefit of sumatriptan to an employer. J Occup Environ Med. 1997;39(7):652-657. (Pubitemid 27327248)
23. Lofland JH, Johnson NE, Batenhorst AS, Nash DB. Changes in resource use and outcomes for patients with migraine treated with sumatriptan: a managed care perspective [published correction appears in Arch Intern Med. 1999; 159(18):2228]. Arch Intern Med. 1999;159(8):857-863.
24. Lofland JH, Gagne JJ, Pizzi LT, Rupnow M, Silberstein SD. Impact of topiramate migraine prophylaxis on workplace productivity: results from two US randomized, double-blind, placebo-controlled, multicenter trials. J Occup Environ Med. 2007;49(3):252-257. (Pubitemid 46411481)
25. Miller DW, Martin BC, Loo CM. Sumatriptan and lost productivity time: a time series analysis of diary data. Clin Ther. 1996;18(6):1263-1275. (Pubitemid 27077129)
26. Mushet GR, Miller DW, Clements B, Pait G, Gutterman DL. Impact of sumatriptan on workplace productivity, nonwork activities, and health-related quality of life among hospital employees with migraine. Headache. 1996;36(3):137-143. (Pubitemid 26116920)
27. Osterhaus JT, Gutterman DL. Plachetka JR. Healthcare resource and lost labour costs of migraine headache in the US. Pharmacoeconomics. 1992;2(1):67-76.
28. Schrader H, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. BMJ. 2001;322(7277):19-22. (Pubitemid 32066251)
29. Schulman EA, Cady RK, Henry D, et al. Effectiveness of sumatriptan in reducing productivity loss due to migraine: results of a randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc. 2000;75(8):782-789. (Pubitemid 30640635)
30. Schwartz BS, Stewart WF, Lipton RB. Lost workdays and decreased work effectiveness associated with headache in the workplace. J Occup Environ Med. 1997;39(4):320-327. (Pubitemid 27183608)
31. Cady RC, Ryan R, Jhingran P, O'Quinn S, Pait DG. Sumatriptan injection reduces productivity loss during a migraine attack: results of a double-blind, placebo-controlled trial. Arch Intern Med. 1998;158(9):1013-1018. (Pubitemid 28213579)
32. Lofland JH, Frick KD. Workplace absenteeism and aspects of access to health care for individuals with migraine headache. Headache. 2006;46(1):563-576.
33. Pransky GS, Berndt E, Finkelstein SN, Verma S, Agrawal A. Performance decrements resulting from illness in the workplace: the effect of headaches. J Occup Environ Med. 2005;47(1):34-40. (Pubitemid 40129011)
34. Stewart WF, Wood GC, Razzaghi H, Reed ML, Lipton RB. Work impact of migraine headaches. J Occup Environ Med. 2008;50(7):736-745.
35. Durham CF, Alden KR, Dalton JA, et al. Quality of life and productivity in nurses reporting migraine. Headache. 1998;38(6):427-435. (Pubitemid 28399172)
36. Goetzel RZ, Ozminkowski RJ, Long SR. Development and reliability analysis of the Work Productivity Short Inventory (WPSI) instrument measuring employee health and productivity. J Occup Environ Med. 2003;45(7):743-762. (Pubitemid 36875651)
37. Ozminkowski RJ, Goetzel RZ, Long SR. A validity analysis of the Work Productivity Short Inventory (WPSI) instrument measuring employee health and productivity. J Occup Environ Med. 2003;45(11):1183-1195. (Pubitemid 37420864)
38. Lofland JH, Locklear JC, Frick KD. Different approaches to valuing the lost productivity of patients with migraine. Pharmacoeconomics. 2001;19(9):917-925. (Pubitemid 32937942)
39. Burton WN, Conti DJ, Chen CY, Schultz AB, Edington DW. The economic burden of lost productivity due to migraine headache: a specific worksite analysis. J Occup Environ Med. 2002;44(6):523-529.
40. Lipton RB, Liberman JN, Kolodner KB, Bigal ME, Dowson A, Stewart WF. Migraine headache disability and health-related quality-of-life: a population- based case-control study from England. Cephalalgia. 2003;23(6):441-450. (Pubitemid 36776060)
41. Magnusson JE, Becker WJ. Migraine frequency and intensity: relationship with disability and psychological factors. Headache. 2003;43(10):1049-1059. (Pubitemid 37543072)
42. Terwindt GM, Ferrari MD, Tijhuis M, Groenen SM, Picavet HS, Launer LJ. The impact of migraine on quality of life in the general population: the GEM study. Neurology. 2000;55(5):624-629.
43. Lofland JH, Kim SS, Batenhorst AS, et al. Cost-effectiveness and cost-benefit of sumatriptan in patients with migraine. Mayo Clin Proc. 2001;76(11):1093-1101. (Pubitemid 33032386)
44. Halpern MT, Lipton RB, Cady RK, Kwong WJ, Marlo KO, Batenhorst AS. Costs and outcomes of early versus delayed migraine treatment with sumatriptan. Headache. 2002;42(10):984-999. (Pubitemid 35470706)
45. Chen BH. Lisinopril for migraine. CMAJ. 2001;164(9):1337. (Pubitemid 32702047)
46. Medtronic announces first clinical data on occipital nerve stimulation for chronic migraine to be presented at American Headache Society Meeting: early data show promise for new application of neurostimulation [press release]. Minneapolis, MN: Medtronic; June 26, 2008. http://wwwp.medtronic.com/Newsroom/ NewsReleaseDetails.do?itemId=1214482108297. Accessed February 10, 2009.
47. Kwong JW, Taylor FR, Adelman JU. The effect of early intervention with sumatriptan tablets on migraine-associated productivity loss. J Occup Environ Med. 2005;47(11):1167-1173. (Pubitemid 41642508)
48. Stewart WF, Lipton RB, Simon D, Von Korff M, Liberman J. Reliability of an illness severity measure for headache in a population sample of migraine sufferers. Cephalalgia. 1998;18(1):44-51. (Pubitemid 28096518)
49. Von Korff M, Stewart WF, Simon DJ, Lipton RB. Migraine and reduced work performance: a population-based diary study. Neurology. 1998;50(6):1741-1745. (Pubitemid 28283244)
50. Stewart WF, Lipton RB, Simon D. Work-related disability: results from the American Migraine Study. Cephalalgia. 1996;16(4):231-238. (Pubitemid 26189248)
51. Weaver MB, Mackowiak JI, Solari PG. Triptan therapy impacts health and productivity. J Occup Environ Med. 2004;46(8):812-817. (Pubitemid 39093772)
52. Collins JJ, Baase CM, Sharda CE, et al. The assessment of chronic health conditions on work performance, absence, and total economic impact for employers. J Occup Environ Med. 2005;47(6):547-557. (Pubitemid 40847438)
53. Gerth WC, Sarma S, Hu XH, Silberstein SD. Productivity cost benefit to employers of treating migraine with rizatriptan: a specific worksite analysis and model. J Occup Environ Med. 2004;46(1):48-54. (Pubitemid 38084574)
54. Loeppke R, Hymel PA, Lofland JH, et al; American College of Occupational and Environmental Medicine. Health-related workplace productivity measurement: general and migraine-specific recommendations from the ACOEM expert panel [published correction appears in J Occup Environ Med. 2003;45(9):940]. J Occup Environ Med. 2003;45(4):349-359.
55. Hymel P, Loeppke R, Baase C, et al. Establishing a research agenda in health and productivity [editorial]. J Occup Environ Med. 2004;46(6):518-520. (Pubitemid 38747696)
56. Warshaw L, Burton W, Schneider W. Role of the workplace in migraine disease management. Dis Manag Health Outcomes. 2001;9(2):99-115. (Pubitemid 32216110)
57. Lipton RB, Silberstein S, Burton W. Relieving an employer's economic headache: ten action steps for managing migraine in the workplace. Am J Integrated Healthcare. 1997;1(1):26-31.
58. Burton WN, Conti DJ, Chen CY, Schultz AB, Edington DW. The impact of allergies and allergy treatment on worker productivity. J Occup Environ Med. 2001;43(1):64-71. (Pubitemid 32098845)
59. Simon GE, Barber C, Birnbaum HG, et al. Depression and work productivity: the comparative costs of treatment versus nontreatment. J Occup Environ Med. 2001;43(1):2-9. (Pubitemid 32098838)
60. Lerner DJ, Amick BC III, Malspeis S, et al. The migraine work and productivity loss questionnaire: concepts and design. Qual Life Res. 1999;8:699-710. (Pubitemid 30331118)
61. Stewart WF, Ricci A, Leotta C, Chee E. Validation of the work and health interview. Pharmacoeconomics. 2004;22(17):1127-1140. (Pubitemid 39665343)
62. Kessler RC, Barber C, Beck A, et al. The World Health Organization Health and Work Performance Questionnaire (HPQ). J Occup Environ Med. 2003;45(2):156-174. (Pubitemid 36228294)
63. Kessler RC, Ames M, Hymel PA, et al. Using the World Health Organization Health and Work Performance Questionnaire (HPQ) to evaluate the indirect workplace costs of illness. J Occup Environ Med. 2004;46(6)(suppl):S23-S37. (Pubitemid 38747691)
64. Schultz AB, Edington DW. Employee health and presenteeism: a systematic review. J Occup Rehabil. 2007 Sep;17(3):547-579. Epub 2007 Jul 25.
65. Koopsmanschap M, Burdorf A, Jacob K, Meerding WJ, Brouwer W, Severens H. Measuring productivity changes in economic evaluation: setting the research agenda. Pharmacoeconomics. 2005;23(1):47-54. (Pubitemid 40194008)
66. Stewart WF, Ricci JA, Leotta C. Health-related lost productive time (LPT): recall interval and bias in LPT estimates. J Occup Environ Med. 2004;46(6)(suppl):S12-S22. (Pubitemid 38747690)
67. Severens JL, Mulder J, Laheij RJ, Verbeek AL. Precision and accuracy in measuring absence from work as a basis for calculating productivity costs in The Netherlands. Soc Sci Med. 2000;51(2):243-249. (Pubitemid 30209963)
68. Devlen J. Anxiety and depression in migraine. J R Soc Med. 1994;87(6):338-341. (Pubitemid 24189018)
69. Andrasik F, Kabela E, Quinn S, Attanasio V, Blanchard EB, Rosenblum EL. Psychological functioning of children who have recurrent migraine. Pain. 1988;34(1):43-52. (Pubitemid 18172278)
70. Buse DC, Bigal ME, Rupnow M, Reed M, Serrano D, Lipton RB. Development and validation of the Migraine Interictal Burden Scale (MIBS): a self-administered instrument for measuring the burden of migraine between attacks [abstract S05.003]. Neurology. 2007;68(suppl 1):A89.